Alkahest
Carl is a physician scientist leader with 24 years combined clinical and biopharma industry experience. He has expertise in translational research, translational medicine, biomarker and diagnostics development, drug development, patient tailoring, companion diagnostics, and experimental pathology. He previously led translational groups focused on immuno-oncology at Atreca and age-related diseases at Unity Biotechnology. His prior industry experience also includes oncology biomarker and clinical development roles at Eli Lilly, and diagnostics development at Genomic Health. Prior to joining the biopharma industry, Carl practiced clinical medicine as a pathologist in academic and private practice settings. After earning his medical degree at Thomas Jefferson Medical College, he completed an anatomic/clinical pathology residency and surgical pathology fellowship training at the University of California, San Francisco.
This person is not in any offices
Alkahest
Alkahest is developing therapies derived from blood to treat neurological diseases, with an emphasis on the age-related cognitive decline - key medical challenges of our generation.